{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:35:53Z","timestamp":1790984153484,"version":"4.1.0"},"reference-count":249,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":1451,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.jcf.2009.04.005","type":"journal-article","created":{"date-parts":[[2009,6,26]],"date-time":"2009-06-26T14:04:09Z","timestamp":1246025049000},"page":"295-315","source":"Crossref","is-referenced-by-count":226,"title":["Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus"],"prefix":"10.1016","volume":"8","author":[{"given":"Harry","family":"Heijerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsbeth","family":"Westerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2009.04.005_bib1","series-title":"Cystic Fibrosis Foundation Patient Registry 2005 Annual Data Report","author":"Cystic Fibrosis Foundation","year":"2006"},{"key":"10.1016\/j.jcf.2009.04.005_bib2","series-title":"Cystic fibrosis","year":"2007"},{"key":"10.1016\/j.jcf.2009.04.005_bib3","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0092-8674(00)81724-9","article-title":"Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease","volume":"95","author":"Matsui","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.jcf.2009.04.005_bib4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(03)12567-6","article-title":"Cystic fibrosis","volume":"361","author":"Ratjen","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2009.04.005_bib5","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1164\/ajrccm.156.4.96-11058","article-title":"Lower airway inflammation in infants and young children with cystic fibrosis","volume":"156","author":"Armstrong","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib6","unstructured":"Stern M, Sens B, Wiedemann B, Busse O. Qualit\u00e4tssicherung Mukoviszidose - \u00dcberblick \u00fcber den Gesundheitszustand der Patienten in Deutschland 2001. Eds, Zentrum f\u00fcr Qualit\u00e4tsmanagement im Gesundheitswesen. \u00c4rztekammer Hannover, 2002."},{"key":"10.1016\/j.jcf.2009.04.005_bib7","first-page":"19","article-title":"The microbiology and therapy of cystic fibrosis lung infections","volume":"1","author":"Govan","year":"1990","journal-title":"Rev Med Microbiol"},{"key":"10.1016\/j.jcf.2009.04.005_bib8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1006\/mpat.1998.0269","article-title":"Haemophilus influenzae localized in epithelial cell layers is shielded from antibiotics and antibody-mediated bactericidal activity","volume":"26","author":"van Schilfgaarde","year":"1999","journal-title":"Microb Pathog"},{"key":"10.1016\/j.jcf.2009.04.005_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/aje\/153.4.345","article-title":"Predictive 5-year survivorship model of cystic fibrosis","volume":"153","author":"Liou","year":"2001","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jcf.2009.04.005_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcf.2004.03.008","article-title":"Early intervention and prevention of lung disease in cystic fibrosis: a European consensus","volume":"3","author":"D\u00f6ring","year":"2004","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2009.04.005_bib11","doi-asserted-by":"crossref","first-page":"5176","DOI":"10.1128\/JCM.42.11.5176-5183.2004","article-title":"Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling","volume":"42","author":"Rogers","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jcf.2009.04.005_bib12","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/JCM.02282-05","article-title":"Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis","volume":"44","author":"Rogers","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jcf.2009.04.005_bib13","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1164\/ajrccm\/141.4_Pt_1.914","article-title":"Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone","volume":"141","author":"Regelmann","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jcf.2009.04.005_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib15","series-title":"Cystic fibrosis","first-page":"83","article-title":"Microbiology of cystic fibrosis","author":"Hoiby","year":"2000"},{"key":"10.1016\/j.jcf.2009.04.005_bib16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ppul.2009.abs","article-title":"Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition","volume":"32","author":"Kosorok","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1172\/JCI0213870","article-title":"Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients","volume":"109","author":"Worlitzsch","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2009.04.005_bib18","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1183\/09031936.00099506","article-title":"Cystic fibrosis mortality and survival in the UK: 1947\u20132003","volume":"29","author":"Dodge","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/ppul.1950070413","article-title":"Safely of aerosol tobramycin administration for 3\u00a0months to patients with cystic fibrosis","volume":"7","author":"Smith","year":"1989","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib20","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1126\/science.288.5469.1251","article-title":"High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection","volume":"288","author":"Oliver","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jcf.2009.04.005_bib21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1086\/509821","article-title":"Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis","volume":"195","author":"Hogardt","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcf.2009.04.005_bib22","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0140-6736(91)91446-2","article-title":"Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment","volume":"338","author":"Valerius","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2009.04.005_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/(SICI)1099-0496(199802)25:2<88::AID-PPUL3>3.0.CO;2-J","article-title":"Placebo controlled, double blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in patients with cystic fibrosis","volume":"25","author":"Wiesemann","year":"1998","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib24","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(01)06124-4","article-title":"Eradication of Pseudomonas aeruginosa with inhaled tobramycin in patients with cystic fibrosis","volume":"358","author":"Ratjen","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2009.04.005_bib25","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1164\/rccm.200208-855OC","article-title":"Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis","volume":"167","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/09031936.05.00009605","article-title":"Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients","volume":"26","author":"Taccetti","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib27","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ppul.20625","article-title":"Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis","volume":"42","author":"Gibson","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib28","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1164\/ajrccm.150.2.8049828","article-title":"Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation","volume":"150","author":"Konstan","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib29","first-page":"69","article-title":"Immunology of cystic fibrosis","author":"D\u00f6ring","year":"2007"},{"key":"10.1016\/j.jcf.2009.04.005_bib30","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199503303321303","article-title":"Effect of high-dose ibuprofen in patients with cystic fibrosis","volume":"332","author":"Konstan","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib31","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.200702-181OC","article-title":"Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis","volume":"176","author":"Konstan","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib32","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0022-3565(24)29557-4","article-title":"In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist","volume":"297","author":"Birke","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jcf.2009.04.005_bib33","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1183\/09031936.00146807","article-title":"Inhibition of airway proteases in cystic fibrosis lung disease","volume":"32","author":"Griese","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib34","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/thorax.57.3.212","article-title":"Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial","volume":"57","author":"Wolter","year":"2002","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2009.04.005_bib35","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(02)11081-6","article-title":"Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial","volume":"360","author":"Equi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2009.04.005_bib36","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jcf.2009.04.005_bib37","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib38","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1080\/08035250600752466","article-title":"Effect of aerosolized rhDNase (Pulmozyme\u00ae) on pulmonary colonization in patients with cystic fibrosis","volume":"95","author":"Frederiksen","year":"2006","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.jcf.2009.04.005_bib39","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1136\/thx.52.10.900","article-title":"Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis","volume":"52","author":"Robinson","year":"1997","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2009.04.005_bib40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib41","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","article-title":"Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus","volume":"16","author":"D\u00f6ring","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib42","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/clinids\/14.3.720","article-title":"Oxygen tensions and infections: modulation of microbial growth, activity of antimicrobial agents, and immunologic responses","volume":"14","author":"Park","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcf.2009.04.005_bib43","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJM199306173282403","article-title":"Efficacy of aerosolized tobramycin in patients with cystic fibrosis","volume":"328","author":"Ramsey","year":"1993","journal-title":"N Engl J Med"},{"issue":"3 Suppl","key":"10.1016\/j.jcf.2009.04.005_bib44","doi-asserted-by":"crossref","first-page":"107S","DOI":"10.1378\/chest.120.3_suppl.107S","article-title":"Administration of aerosolized antibiotics in cystic fibrosis patients","volume":"120","author":"Moss","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1378\/chest.121.1.55","article-title":"Long-term benefits of inhaled tobramycin in adolescents with cystic fibrosis","volume":"121","author":"Moss","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib46","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ppul.20097","article-title":"Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease","volume":"38","author":"Murphy","year":"2004","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1183\/09031936.02.00264002","article-title":"Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis","volume":"20","author":"Nikolaizik","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib48","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1378\/chest.122.3.930","article-title":"Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin","volume":"122","author":"Ho","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib49","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/jac\/19.6.831","article-title":"Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection","volume":"19","author":"Jensen","year":"1987","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcf.2009.04.005_bib50","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1183\/09031936.02.00248102","article-title":"A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis","volume":"20","author":"Hodson","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib51","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jcf.2006.05.009","article-title":"Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis","volume":"5","author":"Adeboyeku","year":"2006","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2009.04.005_bib52","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O","article-title":"Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis","volume":"23","author":"Frederiksen","year":"1997","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib53","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1378\/chest.127.2.522","article-title":"Bronchial constriction and inhaled colistin in cystic fibrosis","volume":"127","author":"Alothman","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib54","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1136\/adc.84.5.432","article-title":"Bronchoconstriction following nebulised colistin in cystic fibrosis","volume":"84","author":"Cunningham","year":"2001","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jcf.2009.04.005_bib55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jcf.2003.12.005","article-title":"Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study","volume":"3","author":"Westerman","year":"2004","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2009.04.005_bib56","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","article-title":"Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis","volume":"178","author":"McCoy","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib57","series-title":"Congress of the International Society for Aerosols in Medicine. Baltimore","article-title":"High efficiency pulmonary drug delivery of a novel formulation of aztreonam by the eFlow\u2122. Poster 030","author":"Keller","year":"2003"},{"key":"10.1016\/j.jcf.2009.04.005_bib58","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ppul.20429","article-title":"Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis","volume":"41","author":"Gibson","year":"2006","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib59","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ppul.20736","article-title":"A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"43","author":"Retsch-Bogart","year":"2008","journal-title":"Pediatr Pulmonol"},{"issue":"S30","key":"10.1016\/j.jcf.2009.04.005_bib60","first-page":"310","article-title":"Phase 3 trial (AIR-CF1) measuring improvement in respiratory symptoms in patients with cystic fibrosis (CF) following treatment with aztreonam lysine for inhalation (AZLI)","volume":"42","author":"Retsch-Bogart","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib61","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0140-6736(86)92960-0","article-title":"Treatment of experimental Legionnaires disease by aerosol administration of rifampicin, ciprofloxacin, and erythromycin","volume":"8479","author":"Fitzgeorge","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2009.04.005_bib62","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1128\/AAC.41.6.1288","article-title":"Ciprofloxacin: aerosol characterisation and efficacy against Francisella tularensis infection in mice","volume":"41","author":"Conley","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"S30","key":"10.1016\/j.jcf.2009.04.005_bib63","first-page":"303","article-title":"Pharmacokinetics and safety of MP-376 (levofloxacin solution for inhalation) in normal healthy volunteers and cystic fibrosis patients","volume":"42","author":"Griffith","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib64","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/jac\/34.6.1001","article-title":"Prophylactic efficacy of aerosolised liposomal (AmBisone) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis","volume":"34","author":"Allen","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcf.2009.04.005_bib65","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1517\/14740338.6.5.523","article-title":"Safety of aerosolised amphotericin B","volume":"6","author":"Knechtel","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jcf.2009.04.005_bib66","series-title":"45th Interscience Conference on antimicrobial agents and chemotherapy","article-title":"Safety and tolerability of nebulised liposomal Amphotericin B in haematologic patients","author":"Ruiz","year":"2005"},{"key":"10.1016\/j.jcf.2009.04.005_bib67","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1399-3062.2007.00209.x","article-title":"Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study","volume":"9","author":"Lowry","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jcf.2009.04.005_bib68","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1345\/aph.1G477","article-title":"Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections","volume":"40","author":"Mohammed","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"S25","key":"10.1016\/j.jcf.2009.04.005_bib69","first-page":"301","article-title":"Weekly nebulisation of liposomal amphotericine B for the treatment of prednisone dependent ABPA","volume":"36","author":"Tiddens","year":"2003","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib70","series-title":"XIIIth International Cystic Fibrosis Congress","first-page":"S256","article-title":"Control of Aspergillus bronchial colonization in cystic fibrosis patients: preliminary data using AmBisone aerosol therapy","author":"Sanchez-Sousa","year":"1996"},{"key":"10.1016\/j.jcf.2009.04.005_bib71","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1378\/chest.110.4.889","article-title":"Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease","volume":"110","author":"McCoy","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib72","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1067\/mpd.2001.118570","article-title":"A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities","volume":"139","author":"Quan","year":"2001","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2009.04.005_bib73","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1378\/chest.128.4.2327","article-title":"Dornase alfa reduces air trapping in children with mild cystic fibrosis","volume":"128","author":"Robinson","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib74","series-title":"The Cochrane Library","article-title":"Recombinant human deoxyribonuclease for cystic fibrosis (Cochrane Review)","author":"Jones","year":"2003"},{"key":"10.1016\/j.jcf.2009.04.005_bib75","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa043891","article-title":"Mucus clearance and lung function in cystic fibrosis with hypertonic saline","volume":"354","author":"Donaldson","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jcf.2009.04.005_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001506.pub2","article-title":"Nebulised hypertonic saline for cystic fibrosis","author":"Wark","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcf.2009.04.005_bib77","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M","article-title":"Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis","volume":"21","author":"Eng","year":"1996","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib78","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0140-6736(01)06412-1","article-title":"Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial","volume":"358","author":"Suri","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2009.04.005_bib79","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1569-1993(01)00009-1","article-title":"Hypertonic saline and recombinant human DNase: a randomised crossover pilot study in patients with cystic fibrosis","volume":"1","author":"Ballmann","year":"2002","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2009.04.005_bib80","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.pupt.2007.12.003","article-title":"Denufosol: a review of studies with inhaled P2Y2 agonists that led to Phase 3","volume":"21","author":"Kellerman","year":"2008","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jcf.2009.04.005_bib81","first-page":"185","article-title":"Uridine 50-triphosphate (UTP) regulates mucociliary clearance via purinergic receptor activation","volume":"37","author":"Drutz","year":"1996","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.jcf.2009.04.005_bib82","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1164\/ajrccm.154.1.8680683","article-title":"Acute safety and effects on mucociliary clearance of aerosolized uridine 50-triphosphate7amiloride in normal human adults","volume":"154","author":"Olivier","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib83","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1124\/jpet.102.035485","article-title":"Pharmacology of INS37217 [P1-(uridine 50)-P4-(20-deoxycytidine 50)tetraphosphate, tetrasodium salt], a next-generation P2Y2 receptor agonist for the treatment ofcystic fibrosis","volume":"302","author":"Yerxa","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jcf.2009.04.005_bib84","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ppul.20192","article-title":"Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1\/phase 2 multicenter study in mild to moderate cystic fibrosis","volume":"39","author":"Deterding","year":"2005","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib85","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1378\/chest.125.1.143","article-title":"A phase I trial of intranasal Moli1901 for cystic fibrosis","volume":"125","author":"Zeitlin","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib86","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1378\/chest.06-2085","article-title":"Inhalation of Moli1901 in patients with cystic fibrosis","volume":"131","author":"Grasemann","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib87","series-title":"Cystic fibrosis","article-title":"Infection and inflammation of the lung in cystic fibrosis","author":"Konstan","year":"1993"},{"key":"10.1016\/j.jcf.2009.04.005_bib88","first-page":"1075","article-title":"Early pulmonary inflammation in infants with cystic fibrosis","volume":"151","author":"Khan","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib89","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1542\/peds.87.2.245","article-title":"Risks of alternate day prednisolone in patients with cystic fibrosis","volume":"87","author":"Rosenstein","year":"1991","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcf.2009.04.005_bib90","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0954-6111(95)90249-X","article-title":"The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis","volume":"89","author":"van Haren","year":"1995","journal-title":"Resp Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib91","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-3476(96)70407-9","article-title":"Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis","volume":"128","author":"Nikolaizik","year":"1996","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2009.04.005_bib92","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/adc.77.2.124","article-title":"Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis","volume":"77","author":"Balfour-Lynn","year":"1997","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jcf.2009.04.005_bib93","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1183\/09031936.99.14511509","article-title":"Effects of short-term inhaled fluticasone on oxidative burst of sputum cells in cystic fibrosis","volume":"14","author":"Dauletbaev","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib94","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00431-006-0198-9","article-title":"Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients?","volume":"166","author":"De Boeck","year":"2007","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jcf.2009.04.005_bib95","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1164\/ajrccm.156.4.9612044","article-title":"Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection","volume":"156","author":"Bisgaard","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib96","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/ppul.1122","article-title":"Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study","volume":"32","author":"Wojtczak","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib97","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1164\/rccm.200511-1808OC","article-title":"Multicenter randomised controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis","volume":"173","author":"Balfour-Lynn","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib98","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001915","article-title":"Inhaled corticosteroids for cystic fibrosis","volume":"1","author":"Balfour-Lynn","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcf.2009.04.005_bib99","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/0140-6736(91)91167-S","article-title":"Aerosol \u03b11-antitrypsin treatment for cystic fibrosis","volume":"337","author":"McElvaney","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2009.04.005_bib100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ppul.20345","article-title":"Safety and efficacy of recombinant alpha1-antitrypsin therapy in cystic fibrosis","volume":"41","author":"Martin","year":"2006","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib101","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1183\/09031936.00047306","article-title":"\u03b11-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients","volume":"29","author":"Griese","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib102","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1183\/09031936.00159606","article-title":"Revisiting \u03b11-antitrypsin therapy in cystic fibrosis: can it still offer promise?","volume":"29","author":"Brennan","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib103","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1164\/ajrccm\/148.4_Pt_1.1056","article-title":"Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolised to normals and individuals with cystic fibrosis","volume":"148","author":"McElvaney","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jcf.2009.04.005_bib104","doi-asserted-by":"crossref","first-page":"261S","DOI":"10.1378\/chest.110.6_Supplement.261S","article-title":"Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity","volume":"110","author":"Vogelmeier","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib105","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1378\/chest.94.2.360","article-title":"Airway hyperreactivity in cystic fibrosis","volume":"94","author":"Eggleston","year":"1988","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib106","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1378\/chest.99.5.1061","article-title":"Long-term inhaled bronchodilator therapy in cystic fibrosis","volume":"99","author":"Orenstein","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib107","first-page":"889","article-title":"A longitudinal study of bronchodilator responsiveness in cystic fibrosis","volume":"131","author":"Hordvik","year":"1985","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jcf.2009.04.005_bib108","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ppul.1950090204","article-title":"Longitudinal response of pulmonary function to bronchodilators in cystic fibrosis","volume":"9","author":"Pattishall","year":"1990","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib109","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1378\/chest.99.5.1088","article-title":"A controlled trial of long-term bronchodilator therapy in cystic fibrosis","volume":"99","author":"Eggleston","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ppul.1950200402","article-title":"Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report","volume":"20","author":"Konig","year":"1995","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib111","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/(SICI)1099-0496(199801)25:1<32::AID-PPUL3>3.0.CO;2-Q","article-title":"A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis","volume":"25","author":"Konig","year":"1998","journal-title":"Pediatr Pulmonol"},{"issue":"Suppl1","key":"10.1016\/j.jcf.2009.04.005_bib112","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S1569-1993(06)80173-6","article-title":"A retrospective study to assess the response to nebulised salbutamol during a period of stability in adult patients with cystic fibrosis","volume":"5","author":"Hughes","year":"2006","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2009.04.005_bib113","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1378\/chest.06-1697","article-title":"Effect of albuterol on maximal exercise capacity in cystic fibrosis","volume":"131","author":"Serisier","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib114","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jcf.2004.11.004","article-title":"Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis","volume":"4","author":"Dodd","year":"2005","journal-title":"J Cystic Fibros"},{"key":"10.1016\/j.jcf.2009.04.005_bib115","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1183\/09031936.97.10102307","article-title":"Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients","volume":"10","author":"Bargon","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib116","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ppul.10162","article-title":"Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis","volume":"34","author":"Hordvik","year":"2002","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib117","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ppul.10117","article-title":"Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis","volume":"34","author":"Salvatore","year":"2002","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib118","first-page":"CD003428","article-title":"Inhaled bronchodilators for cystic fibrosis","volume":"4","author":"Halfhide","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jcf.2009.04.005_bib119","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1164\/arrd.1985.131.4.537","article-title":"Bronchodilators increase airway instability in cystic fibrosis","volume":"131","author":"Zach","year":"1985","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jcf.2009.04.005_bib120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ppul.1950040404","article-title":"Airway obstruction and airway wall instability in cystic fibrosis: the isolated and combined effects of theophylline and sympathomimetics","volume":"4","author":"Eber","year":"1988","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib121","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1378\/chest.113.1.55","article-title":"No paradoxical bronchodilator response with forced oscillation technique in children with cystic fibrosis","volume":"113","author":"Hellinckx","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib122","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1183\/09031936.93.05091089","article-title":"Comparison of nebulised and intravenous terbutaline during exacerbations of pulmonary infection in patients with cystic fibrosis","volume":"5","author":"Finnegan","year":"1992","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib123","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1164\/ajrccm.154.1.8680672","article-title":"The effects of albuterol on the lung function of hospitalised patients with cystic fibrosis","volume":"154","author":"Hordvik","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib124","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/(SICI)1099-0496(199901)27:1<43::AID-PPUL9>3.0.CO;2-E","article-title":"Effects of standard and high doses of salmeterol on lung function of hospitalised patients with cystic fibrosis","volume":"27","author":"Hordvik","year":"1999","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib125","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1378\/chest.95.4.861","article-title":"The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF","volume":"95","author":"Weintraub","year":"1989","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib126","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ppul.1071","article-title":"Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis","volume":"31","author":"Ziebach","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib127","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0022-3476(05)80927-8","article-title":"Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis","volume":"120","author":"Sanchez","year":"1992","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2009.04.005_bib128","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1378\/chest.104.3.842","article-title":"The effect of high doses of inhaled salbutamol and ipratropium bromide in patients with stable cystic fibrosis","volume":"104","author":"Sanchez","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib129","series-title":"Handbook on injectable drugs","author":"Trissel","year":"2006"},{"key":"10.1016\/j.jcf.2009.04.005_bib130","unstructured":"Anonymous. Drugdex database: http:\/\/www.thomsonhc.com, consulted on 10th December 2007a."},{"key":"10.1016\/j.jcf.2009.04.005_bib131","unstructured":"Anonymous. The King guide to parenteral admixtures, Loose leaf version, 2007b."},{"key":"10.1016\/j.jcf.2009.04.005_bib132","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1128\/AAC.49.4.1377-1380.2005","article-title":"Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane","volume":"49","author":"Imamura","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcf.2009.04.005_bib133","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/infdis\/124.6.610","article-title":"Activity of colistin against Pseudomonas aeruginosa. Inhibition by calcium","volume":"124","author":"Davis","year":"1971","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jcf.2009.04.005_bib134","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jcf.2006.03.007","article-title":"Inhalation solutions: which ones are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers","volume":"5","author":"Kamin","year":"2006","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2009.04.005_bib135","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1089\/jam.2006.19.484","article-title":"Nebulized drug admixtures: effect on aerosol characteristics and albuterol output","volume":"19","author":"Berlinski","year":"2006","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib136","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1378\/chest.111.5.1206","article-title":"The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols","volume":"111","author":"Coates","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib137","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/08942680152007909","article-title":"Aerosols and anti-infectious agents","volume":"14","author":"Diot","year":"2001","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib138","first-page":"155","article-title":"Comparative study of the performance and ergonomics of nebulizers in cystic fibrosis","volume":"13","author":"Faurisson","year":"1996","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.jcf.2009.04.005_bib139","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1164\/ajrccm\/136.6.1445","article-title":"Quantitative deposition of aerosolized gentamicin in cystic fibrosis","volume":"136","author":"Ilowite","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.jcf.2009.04.005_bib140","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0140-6736(90)91880-J","article-title":"Dilution of nebulised aerosols by air entrainment in children","volume":"336","author":"Collis","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2009.04.005_bib141","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1183\/09031936.97.10112479","article-title":"Comparison of drug delivery from conventional versus \u201cVenturi\u201d nebulizers","volume":"10","author":"Devadason","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib142","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1183\/09031936.97.10092023","article-title":"Lung deposition from the Turbuhaler in children with cystic fibrosis","volume":"10","author":"Devadason","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib143","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/thx.43.4.318","article-title":"Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern","volume":"43","author":"Newman","year":"1988","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2009.04.005_bib144","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/jam.2005.18.45","article-title":"Optimum peripheral drug deposition in patients with cystic fibrosis","volume":"18","author":"Brand","year":"2005","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib145","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/jam.2005.18.283","article-title":"Evaluation of nebulizer performance under various humidity conditions","volume":"18","author":"Zhou","year":"2005","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib146","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1164\/rccm.200308-1104OC","article-title":"Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis","volume":"169","author":"Griese","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib147","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1128\/AAC.41.1.184","article-title":"Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis","volume":"41","author":"Touw","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcf.2009.04.005_bib148","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1183\/09031936.01.99086801","article-title":"Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis","volume":"18","author":"Dequin","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib149","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1592\/phco.22.8.557.33202","article-title":"Tobramycin as a pharmacologic tracer to compare airway deposition from nebulizers","volume":"22","author":"Asmus","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jcf.2009.04.005_bib150","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/jam.2004.17.231","article-title":"Intra-subject variability in lung dose in healthy volunteers using five conventional portable inhalers","volume":"17","author":"Aswania","year":"2004","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib151","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0022-3476(74)80664-5","article-title":"Pulmonary deposition of aerosols in children with cystic fibrosis","volume":"84","author":"Alderson","year":"1974","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2009.04.005_bib152","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1183\/09031936.94.07122185","article-title":"The influence of age on aerosol deposition in children with cystic fibrosis","volume":"7","author":"Chua","year":"1994","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib153","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0954-6111(05)80348-8","article-title":"The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis","volume":"88","author":"Mukhopadhyay","year":"1994","journal-title":"Respir Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib154","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1164\/ajrccm.156.5.9604093","article-title":"RhDNase I aerosol deposition and related factors in cystic fibrosis","volume":"156","author":"Diot","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib155","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1183\/09031936.97.10091995","article-title":"Nebulization and anti-Pseudomonas aeruginosa activity of colistin","volume":"10","author":"Diot","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib156","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/08942680152744659","article-title":"Regional deposition of coarse particles and ventilation distribution in healthy subjects and patients with cystic fibrosis","volume":"14","author":"Brown","year":"2001","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib157","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1081\/DDC-100000238","article-title":"Deposition of nacystelyn from a dry powder inhaler in healthy volunteers and cystic fibrosis patients","volume":"27","author":"Vanderbist","year":"2001","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.jcf.2009.04.005_bib158","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/adc.88.8.715","article-title":"Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis","volume":"88","author":"Byrne","year":"2003","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jcf.2009.04.005_bib159","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejpb.2007.05.005","article-title":"Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients","volume":"68","author":"Pilcer","year":"2008","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.jcf.2009.04.005_bib160","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0939-6411(02)00044-9","article-title":"Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients","volume":"54","author":"Le Brun","year":"2002","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.jcf.2009.04.005_bib161","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2006.10.010","article-title":"Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study","volume":"6","author":"Westerman","year":"2007","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2009.04.005_bib162","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ppul.20594","article-title":"Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety","volume":"42","author":"Geller","year":"2007","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib163","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/089426803764928347","article-title":"Lung deposition in cystic fibrosis patients using an ultrasonic or a jet nebulizer","volume":"16","author":"Kohler","year":"2003","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib164","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1089\/0894268041457192","article-title":"Does wearing a nose clip during inhalation improve lung deposition?","volume":"17","author":"Kohler","year":"2004","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib165","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0378-5173(99)00252-5","article-title":"Inhalation of tobramycin in cystic fibrosis. Part 2: optimization of the tobramycin solution for a jet and an ultrasonic nebulizer","volume":"189","author":"Le Brun","year":"1999","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jcf.2009.04.005_bib166","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/00007691-199912000-00007","article-title":"Can tobramycin inhalation be improved with a jet nebulizer?","volume":"21","author":"Le Brun","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jcf.2009.04.005_bib167","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1378\/chest.122.1.219","article-title":"Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis","volume":"122","author":"Geller","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib168","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1183\/09031936.94.07061177","article-title":"Efficient drug delivery to the lungs from a continuously operated open-vent nebulizer and low pressure compressor system","volume":"7","author":"Newman","year":"1994","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib169","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1089\/jam.2005.18.386","article-title":"Lung deposition after electronically breath-controlled inhalation and manually triggered conventional inhalation in cystic fibrosis patients","volume":"18","author":"Kohler","year":"2005","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib170","first-page":"388","article-title":"Pharmacoscintigraphy of TOBI\u00ae in the Pari LC Plus\u2122 and the Aerodose\u2122 inhaler","volume":"14","author":"Newman","year":"2001","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib171","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1089\/jam.2007.0620","article-title":"The challenges of quantitative measurement of lung deposition using 99mTc-DTPA from delivery systems with very different delivery times","volume":"20","author":"Coates","year":"2007","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib172","series-title":"European Respiratory Society Annual Congress, Stockholm","article-title":"Lung deposition of 99mTc-DTPA delivered with an adaptive aerosol delivery system. Abstract 3264","author":"Nikander","year":"2007"},{"key":"10.1016\/j.jcf.2009.04.005_bib173","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1378\/chest.118.4.1069","article-title":"Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate","volume":"118","author":"Laube","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib174","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijpharm.2003.09.004","article-title":"The choice of a compressor for the aerosolisation of tobramycin (TOBI) with the PARI LC PLUS reusable nebuliser","volume":"268","author":"de Boer","year":"2003","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jcf.2009.04.005_bib175","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/jamp.2007.0674","article-title":"Aerosolization of tobramycin (TOBI\u00ae) with the PARI LC PLUS\u00ae reusable nebulizer: which compressor to use? Comparison of the CR60\u00ae to the PortaNeb\u00ae compressor","volume":"21","author":"Westerman","year":"2008","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.jcf.2009.04.005_bib176","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1378\/chest.97.6.1327","article-title":"Droplets produced by medical nebulizers. Some factors affecting their size and solute concentration","volume":"97","author":"Phipps","year":"1990","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib177","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1089\/08942680152744677","article-title":"Evaluation of four breath-enhanced nebulizers for home use","volume":"7","author":"Ho","year":"2001","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib178","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1378\/chest.126.5.1619","article-title":"Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency","volume":"126","author":"Leung","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib179","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1136\/adc.67.5.586","article-title":"Drug delivery from jet nebulisers","volume":"67","author":"Everard","year":"1992","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jcf.2009.04.005_bib180","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0954-6111(93)90135-M","article-title":"Salbutamol output from two jet nebulizers","volume":"87","author":"Langford","year":"1993","journal-title":"Respir Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib181","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1023\/A:1016205520044","article-title":"Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers","volume":"12","author":"McCallion","year":"1995","journal-title":"Pharm Res"},{"key":"10.1016\/j.jcf.2009.04.005_bib182","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-5173(95)04233-4","article-title":"Jet nebulisers for pulmonary drug delivery","volume":"130","author":"McCallion","year":"1996","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jcf.2009.04.005_bib183","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/(SICI)1099-0496(199704)23:4<249::AID-PPUL2>3.0.CO;2-H","article-title":"Effect of nebulizer type and antibiotic concentration on device performance","volume":"23","author":"Weber","year":"1997","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib184","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/jam.1997.10.13","article-title":"Effect of nebulizer configuration on delivery of aerosolized tobramycin","volume":"10","author":"O'Riordan","year":"1997","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib185","unstructured":"Touw DJ. Optimization of tobramycin treatment in cystic fibrosis: a pharmacokinetic approach. Thesis Rijksuniversiteit Leiden 1996; (Chapter 10):179\u2013188."},{"key":"10.1016\/j.jcf.2009.04.005_bib186","first-page":"609","article-title":"Nebulizers: principles and performance","volume":"45","author":"Hess","year":"2000","journal-title":"Respir Care"},{"key":"10.1016\/j.jcf.2009.04.005_bib187","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1378\/chest.87.4.512","article-title":"Efficiency of air compressor-driven nebulizers","volume":"87","author":"Kradjan","year":"1985","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib188","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1155\/1999\/236068","article-title":"Effect of dead volume on the efficiency and the cost to deliver medications in cystic fibrosis with four disposable nebulizers","volume":"6","author":"Ho","year":"1999","journal-title":"Can Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib189","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1517\/17425247.1.1.165","article-title":"Adaptive aerosol delivery (AAD\u00ae) technology","volume":"1","author":"Denyer","year":"2004","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.jcf.2009.04.005_bib190","doi-asserted-by":"crossref","unstructured":"Li Z, Zhang Y, Wurtz BS et al. Characterization of nebulized liposomal amikacin (Arikace\u2122) as a function of droplet size. J Aerosol Med ahead of print. doi:10.1089\/jamp.2008.0686.","DOI":"10.1089\/jamp.2008.0686"},{"key":"10.1016\/j.jcf.2009.04.005_bib191","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(83)90679-7","article-title":"Assessment of jet nebulisers for lung aerosol therapy","volume":"2","author":"Clay","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2009.04.005_bib192","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/thx.40.9.671","article-title":"Evaluation of jet nebulisers for use with gentamicin solution","volume":"40","author":"Newman","year":"1985","journal-title":"Thorax"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2009.04.005_bib193","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1089\/jam.1994.7.Suppl_1.S-19","article-title":"Drug delivery systems","volume":"7","author":"Nikander","year":"1994","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib194","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejps.2005.11.013","article-title":"Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses","volume":"28","author":"de Boer","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.jcf.2009.04.005_bib195","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1089\/jam.2006.19.456","article-title":"Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older","volume":"19","author":"Tiddens","year":"2006","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib196","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1164\/rccm.200410-1414OC","article-title":"Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size","volume":"172","author":"Usmani","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib197","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1513\/pats.200409-046TA","article-title":"Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery","volume":"1","author":"Heyder","year":"2004","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.jcf.2009.04.005_bib198","first-page":"419","article-title":"Positive expiratory pressure (PEP) as lung physiotherapy in cystic fibrosis: a pilot study","volume":"65","author":"Tonnesen","year":"1984","journal-title":"Eur J Respir Dis"},{"key":"10.1016\/j.jcf.2009.04.005_bib199","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1378\/chest.123.1.28","article-title":"Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system","volume":"123","author":"Geller","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib200","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1378\/chest.111.4.955","article-title":"A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group","volume":"111","author":"Eisenberg","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib201","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1378\/chest.114.2.577","article-title":"Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation","volume":"114","author":"Standaert","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib202","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1183\/09031936.97.10061261","article-title":"An evaluation of two aerosol delivery systems for rhDNase","volume":"10","author":"Shah","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2009.04.005_bib203","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1378\/chest.110.2.498","article-title":"Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand","volume":"110","author":"Hess","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib204","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1378\/chest.113.4.951","article-title":"A comparison of the availability of tobramycin for inhalation from vented vs unvented nebulizers","volume":"113","author":"Coates","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib205","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1081-1206(10)62906-7","article-title":"Characterization of aerosol output from various nebulizer\/compressor combinations","volume":"86","author":"Reisner","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jcf.2009.04.005_bib206","unstructured":"Van Erp C, de Boer A, Frijlink E, Heijerman H, Sluyter T, Rottier B. Comparative performance evaluation of PARI eFlow\u00ae Rapid and PARI LC\u00ae Plus nebulizers before and after 6\u00a0months use with tobramycin solution (TOBI\u00ae). Pediatr Pulmonol Suppl; 30:342\u2013343."},{"key":"10.1016\/j.jcf.2009.04.005_bib207","series-title":"ATS Conference AJRCCM","first-page":"A782","article-title":"Use of I-neb\u00ae AAD\u00ae patient logging system data to identify aerosol treatment issues in patients with cystic fibrosis","author":"Dyche","year":"2007"},{"key":"10.1016\/j.jcf.2009.04.005_bib208","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/jam.1994.7.229","article-title":"A nebulizer system for highly reproducible aerosol delivery","volume":"7","author":"Knoch","year":"1994","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib209","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/thx.49.8.762","article-title":"Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system (\u201cVentstream\u201d)","volume":"49","author":"Newnham","year":"1994","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2009.04.005_bib210","unstructured":"Committee for medicinal products for human use (CHMP). Guideline on the pharmaceutical quality of inhalation and nasal products. EMEA\/CHMP\/QWP\/49313\/2005 Corr, 2006."},{"key":"10.1016\/j.jcf.2009.04.005_bib211","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/bmj.295.6602.812","article-title":"Bacterial contamination of home nebuliser","volume":"295","author":"Barnes","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jcf.2009.04.005_bib212","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0022-3476(87)80069-0","article-title":"Pseudomonas species contamination of cystic fibrosis patients' home inhalation equipment","volume":"111","author":"Pitchford","year":"1987","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2009.04.005_bib213","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1128\/JCM.34.3.584-587.1996","article-title":"Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis","volume":"34","author":"Hutchinson","year":"1996","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jcf.2009.04.005_bib214","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0195-6701(97)90195-X","article-title":"Low bacterial contamination of nebulizers in home treatment of cystic fibrosis patients","volume":"36","author":"Jakobsson","year":"1997","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.jcf.2009.04.005_bib215","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0022-3476(98)70497-4","article-title":"Home nebulizer use among patients with cystic fibrosis","volume":"132","author":"Rosenfeld","year":"1998","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2009.04.005_bib216","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1067\/mpd.2001.117785","article-title":"Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis","volume":"139","author":"Rosenfeld","year":"2001","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2009.04.005_bib217","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1053\/jhin.2001.1083","article-title":"Cleaning home nebulizers used by patients with cystic fibrosis: is rinsing with tap water enough?","volume":"49","author":"Rosenfeld","year":"2001","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.jcf.2009.04.005_bib218","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1067\/mic.2000.110214","article-title":"Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis","volume":"28","author":"Vassal","year":"2000","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.jcf.2009.04.005_bib219","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/CMR.17.1.57-71.2004","article-title":"Infection control in cystic fibrosis","volume":"17","author":"Saiman","year":"2004","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jcf.2009.04.005_bib220","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/jhin.1999.0658","article-title":"Low level of bacterial contamination of mist tents used in home treatment of cystic fibrosis patients","volume":"44","author":"Jakobsson","year":"2000","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.jcf.2009.04.005_bib221","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/(SICI)1099-0496(199808)26:2<81::AID-PPUL2>3.0.CO;2-K","article-title":"Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis","volume":"26","author":"Kosorok","year":"1998","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib222","first-page":"258","article-title":"A day in the life of a nebulizer: surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting","volume":"52","author":"O'Malley","year":"2007","journal-title":"Respir Care"},{"key":"10.1016\/j.jcf.2009.04.005_bib223","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/j.2048-7940.1995.tb01629.x","article-title":"Comparison study of home catheter cleaning methods","volume":"20","author":"Kurtz","year":"1995","journal-title":"Rehabil Nurs"},{"key":"10.1016\/j.jcf.2009.04.005_bib224","first-page":"10","article-title":"Catheter cleaning for re-use in intermittent catheterization: new light on an old problem","volume":"12","author":"Lavallee","year":"1995","journal-title":"SCI Nurs"},{"key":"10.1016\/j.jcf.2009.04.005_bib225","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0022-3476(85)80511-4","article-title":"Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome","volume":"107","author":"Tablan","year":"1985","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2009.04.005_bib226","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1067\/mpd.2002.127665","article-title":"Risk factors for Burkholderia cepacia complex colonization and infection among patients with cystic fibrosis","volume":"141","author":"Walsh","year":"2002","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2009.04.005_bib227","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jcf.2006.12.008","article-title":"Does repeated disinfection of the e-Flow rapid nebulizer affect in vitro performance?","volume":"6","author":"Bakuridze","year":"2007","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2009.04.005_bib228","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jcf.2005.06.001","article-title":"In vitro evaluation of efficacy of 5 methods of disinfection on mouthpieces and facemasks contaminated by strains of cystic fibrosis patients","volume":"4","author":"Reychler","year":"2005","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2009.04.005_bib229","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1086\/501694","article-title":"Antimicrobial activity of home disinfectants and natural products against potential human pathogens","volume":"21","author":"Rutala","year":"2000","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jcf.2009.04.005_bib230","first-page":"179","article-title":"A comparison of acetic acid with a quaternary ammonium compound for disinfection of hand-held nebulizers","volume":"33","author":"Chatburn","year":"1988","journal-title":"Respir Care"},{"key":"10.1016\/j.jcf.2009.04.005_bib231","first-page":"1504","article-title":"Nebulizer use and maintenance by cystic fibrosis patients: a survey study","volume":"49","author":"Lester","year":"2004","journal-title":"Respir Care"},{"key":"10.1016\/j.jcf.2009.04.005_bib232","first-page":"267","article-title":"Transmission of gram-negative bacilli to asthmatic children via home nebulizers","volume":"66","author":"Wexler","year":"1991","journal-title":"Ann Allergy"},{"key":"10.1016\/j.jcf.2009.04.005_bib233","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0195-6701(96)90035-3","article-title":"The environmental risk factors associated with medical and dental equipment in the transmission of Burkholderia (Pseudomonas) cepacia in cystic fibrosis patients","volume":"32","author":"Pankhurst","year":"1996","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.jcf.2009.04.005_bib234","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1017\/S0195941700056423","article-title":"Guideline for prevention of nosocomial pneumonia","volume":"3","author":"Simmons","year":"1982","journal-title":"Infect Control"},{"key":"10.1016\/j.jcf.2009.04.005_bib235","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1034\/j.1399-3003.2000.15d22.x","article-title":"Tumour necrosis factor-alpha production in human alveolar macrophages: modulation by inhaled corticosteroid","volume":"15","author":"Marshall","year":"2000","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2009.04.005_bib236","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1089\/jam.1994.7.Suppl_1.S-25","article-title":"Deposition patterns of nebulized drugs: is the pattern important?","volume":"7","author":"Smaldone","year":"1994","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.jcf.2009.04.005_bib237","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1152\/jappl.1987.62.4.1603","article-title":"Human variation in the peripheral air-space deposition of inhaled particles","volume":"62","author":"Bennett","year":"1987","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.jcf.2009.04.005_bib238","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/(SICI)1520-6017(200006)89:6<724::AID-JPS3>3.0.CO;2-B","article-title":"Total deposition of therapeutic particles during spontaneous and controlled inhalations","volume":"89","author":"Brand","year":"2000","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jcf.2009.04.005_bib239","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1023\/A:1016294805680","article-title":"Aerosol deposition as a function of airway disease: cystic fibrosis","volume":"12","author":"Martonen","year":"1995","journal-title":"Pharm Res"},{"key":"10.1016\/j.jcf.2009.04.005_bib240","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/(SICI)1099-0496(199605)21:5<276::AID-PPUL2>3.0.CO;2-L","article-title":"Aerosol deposition in infants with cystic fibrosis","volume":"21","author":"Mallol","year":"1996","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2009.04.005_bib241","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jcf.2006.06.002","article-title":"Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis","volume":"6","author":"Clavel","year":"2007","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2009.04.005_bib242","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1345\/aph.1D335","article-title":"Compatibility of budesonide inhalation suspension with four nebulizing solutions","volume":"38","author":"McKenzie","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jcf.2009.04.005_bib243","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/ajhp\/62.8.828","article-title":"Compatibility and osmolality of inhaled N-acetylcysteine nebulizing solution with fenoterol and ipratropium","volume":"62","author":"Lee","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jcf.2009.04.005_bib244","first-page":"760","article-title":"Physiochemical compatibility of nebulizible drug mixtures containing dornase alfa and ipatropium and\/or albuterol","volume":"62","author":"Kraemer","year":"2007","journal-title":"Pharmazie"},{"key":"10.1016\/j.jcf.2009.04.005_bib245","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-5173(98)00055-6","article-title":"Regional lung deposition of nibulised liposome encapsulated ciproflexacin","volume":"167","author":"Finlay","year":"1998","journal-title":"Int J Pharm"},{"key":"10.1016\/j.jcf.2009.04.005_bib246","unstructured":"MICROMEDEX Healthcare Series. Drugdex Drug Evaluations (2007)."},{"key":"10.1016\/j.jcf.2009.04.005_bib247","unstructured":"Rau JL. Design principles of liquid nebulization devices currently in use Respir Care 2002;47(11):1257\u201375."},{"issue":"5","key":"10.1016\/j.jcf.2009.04.005_bib248","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1378\/chest.111.5.1361","article-title":"Measuring nebulizer output. Aerosol production vs gravimetric analysis","volume":"111","author":"Tandon","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2009.04.005_bib249","doi-asserted-by":"crossref","unstructured":"Vecellio None L, Grimbert D, Bordenave J, Benoit G, Furet Y, Fauroux B, et al. Residual gravimetric method to measure nebulizer output. J Aerosol Med 2004 Spring;17(1):63\u201371.","DOI":"10.1089\/089426804322994479"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199309000356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199309000356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T11:57:09Z","timestamp":1739188629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199309000356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":249,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1569199309000356"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2009.04.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}